Abstract. A significant problem in the use of radiation and chemotherapy drugs is the development of resistance to these agents by recurrent and metastatic tumors. A number of mechanisms have been proposed for chemotherapy and radiation resistance. Previous studies have suggested that resistant cancer cells are more tolerant of DNA damage than sensitive cells. Overexpression of the multiple drug resistance gene P-glycoprotein, which acts as a drug efflux pump, has been implicated in drug resistance. The glutathione-S-X gene has also been shown to be involved in drug resistance. The increased expression of a number of proto-oncogenes, including AP-1, c-myc and ras, has been associated with chemotherapy resistance. Given the number of reported radiation and chemotherapy resistance genes in cancer, we took a global gene expression approach to examine differences between sensitive and resistant cells and their response to different types of DNA damage. We demonstrated increased numbers of responsive genes in sensitive normal epidermal keratinocytes compared to resistant squamous cell carcinoma cells, regardless of the type of DNA damage. Our results also show new genes that may be responsible for chemotherapy resistance in cancer cells, and differences in how sensitive and resistant cells respond to specific types of DNA damage.
Introduction
In patients with advanced cancer, long term, disease-free and survival rates are low. For example, half the number of patients with advanced head and neck squamous cell carcinoma will experience recurrence in 2 years, with 25% developing metastatic disease (1) . Chemotherapy has been integrated with radiation and surgery for locally-advanced disease. The addition of chemotherapy to surgery and radiotherapy improves clinical outcomes in patients with advanced local disease (2) (3) (4) . Concomitant chemoradiotherapy was associated with absolute survival benefit at 5 years follow-up (5) . The combination of cis-diamminedichloroplatinum(II) (cisplatin) and 5-fluorouracil (5-FU) has established activity against squamous cell carcinoma of the head and neck region and has been considered standard therapy for many years (6) . Induction chemotherapy with these drugs produces high overall response rates, with complete response in half the number of patients (7) . These protocols have defined new treatment paradigms for cancer patients (8) .
Anti-proliferative cancer therapy, such as radiation and chemotherapy, is an important part of cancer treatment and is curative for certain types of cancer. These therapies have resulted in improved cure rates when used as adjuvants to surgery. In metastatic disease, anti-proliferative therapy has an increasing role in reducing tumor burden and improving survival. New agents target specific molecules expressed by tumor cells, such as telomerase (9) . However, anti-proliferative therapy has significant limitations, among which are toxic effects on normal cells. One of these effects is DNA damage, which induces growth arrest or cell death (reviewed in ref. 10 ). Understanding how anti-proliferative therapy induces DNA damage and the mechanisms by which normal and cancer cells repair these defects is fundamental to improving therapeutic response, minimizing toxic side effects and maximizing patient survival.
A significant problem in the use of radiation and chemotherapy drugs is the development of resistance to these agents by recurrent and metastatic tumors. A number of mechanisms have been proposed for chemotherapy and radiation resistance. Previous studies have suggested that resistant cancer cells are more tolerant of DNA damage than sensitive cells (11) . Overexpression of the multiple drug resistance gene P-glycoprotein, which acts as a drug efflux pump, has been implicated in drug resistance (12) . The glutathione-S-X gene has also been shown to be involved in drug resistance (13) . Increased expression of a number of proto-oncogenes, including AP-1, c-myc and ras, has been associated with chemotherapy resistance (14) (15) (16) . Given the number of reported radiation and chemotherapy resistance genes in cancer, we took a global gene expression approach to examine the differences between sensitive and resistant cells and their response to different types of DNA damage. We demonstrated increased numbers of responsive genes in sensitive normal epidermal keratinocytes as compared to resistant squamous cell carcinoma cells, regardless of the type of DNA damage. Our results also show new genes that may be responsible for chemotherapy resistance in cancer cells, and differences in how sensitive and resistant cells respond to specific types of DNA damage. Table I . Gene expression changes between NHEK and SCC25 cells (2985 differentially-expressed genes). 
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Eagle's medium (DMEM), 10% fetal bovine serum, 40 μg/ml gentamicin at 37˚C in a humidified atmosphere of 5% CO 2 . NHEK cells were expanded in keratinocyte growth medium (Clonetics) prior to culture in DMEM, 10% fetal bovine serum, 40 μg/ml gentamicin to minimize variability in culture methods. NHEK and SCC25 cultures were treated with 1 or 6 Gy ionizing radiation from a 60 Co source (Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA), 2 or 8 μg/ml cis-diamminedichloroplatinum(II), 10 or 30 μg/ml 5-FU, or 10 μM BIBR1532 (telomerase inhibitor, 9) for 16 h. The respective dosages of ionizing radiation, cisplatin and 5-FU were chosen based on their ability to produce a 50% reduction in cell viability 48 h after treatment.
RNA extraction and gene expression profiling. Total-RNA was extracted from cell cultures using a commercially available kit (RNeasy, Qiagen, Valencia, CA). Three independent samples from each group were used in this gene expression analysis. The integrity of ribosomal RNA bands was confirmed by Northern gel electrophoresis. Total-RNA (10 μg) with spike in controls was first reverse transcribed using a T7-Oligo(dT) promoter primer in the first-strand cDNA synthesis reaction. Following RNase H-mediated second-strand cDNA synthesis, the double-stranded cDNA was purified and served as a template in the subsequent in vitro transcription (IVT) reaction. The IVT reaction was carried out in the presence of T7 RNA polymerase and a biotinylated nucleotide analog/ribonucleotide mix for complementary RNA (cRNA) amplification and biotin labeling. The biotinylated cRNA targets were then purified, fragmented and hybridized to Affymetrix GeneChip expression arrays (Santa Clara, CA). The human genome U133 microarray was used to interrogate transcripts in each sample (Genomics Core Facility, Children's Hospital, Los Angeles, CA). After washing, hybridization signals were detected using streptavidin conjugated phycoerythrin. Affymetrix GCOS software was used to generate raw gene expression scores and normalized to the relative hybridization signal from each experiment. All gene expression scores were set to a minimum value of 2 x the background, determined by GCOS software, in order to minimize noise associated with less robust measurements of rare transcripts. Normalized gene expression data was imported into dChip software (http://www.biostat.harvard.edu/complab/ dchip) for hierarchical clustering analysis using the average linkage algorithm. Raw data was analyzed for quality control and the significance of differential gene expression was determined using the t-test (p<0.005) and ratio analysis (>2-fold).
Results
Initially, we compared gene expression between NHEK cells and the cancer cell line SCC25 (Table I ). This comparison identified almost 3000 differentially-expressed genes. A number of DNA damage response genes were upregulated in SCC25 cells, including RAD51C (18.1-fold), the Fanconi anemia complementation group B (14.7-fold), RAD1 homolog (14.4-fold), RAD52 homolog B (7.5-fold), the mutS homolog 5 (5.9-fold), X-ray repair complementing defective repair 3 (5.7-fold) and the mutY homolog (5.6-fold). DNA synthesis genes were also upregulated, including mitochondrial topoisomerase (DNA) I (6.5-fold), thymidylate synthetase (6.4-fold) and DNA-directed polymerase ε4 (5.0-fold). The upregulation of viral oncogene homolog v-myb (32.1-fold), Mdm2-transformed 3T3 cell double minute 2 (8.9-fold) and glutathione S-transferase θ1 (5.9-fold) genes was also noted. Downregulation of excision repair cross-complementing group 1 (-5.0-fold) was observed as well. These results indicate that the expression of genes regulating DNA synthesis and damage response is upregulated in SCC25 cells compared to normal keratinocytes.
To determine the response of normal keratinocytes and squamous cell carcinoma cells to different forms of DNA damage, we first treated NHEK or SCC25 cells with ionizing radiation. Expression of 840 genes in NHEK cells was altered by ionizing radiation compared to 468 differentially-expressed genes in the SCC25 line. As shown in Table II . A number of cell cycle and DNA damage repair mRNAs were downregulated (cell division cycle 2, -5.1-fold; excision repair deficiency group 2, -5.1-fold; Fanconi anemia complementation group A, -5.4-fold; topoisomerase 1, -7.4-fold; aurora kinase B, -7.4-fold; cell division cycle 25C, -12.4-fold; cyclin B2, -13.5-fold; topoisomerase IIα, -18.1-fold; cyclin A2, -24.7-fold; cyclin B1, -31.8-fold). These results indicate that downregulation of cell cycle regulatory gene expression is associated with increased terminal differentiation of NHEK cells in response to ionizing radiation.
In contrast, SCC25 cells did not exhibit the same profile as differentially-expressed genes in response to ionizing radiation, nor was the magnitude of changes in gene expression as large as in NHEK cells (Table III) . Heparin-binding EGF-like growth factor was upregulated 10-fold in radiation-exposed SCC25 cells, while insulin-like growth factor 1 receptor was downregulated (-5.5-fold). Epidermal growth factor receptor (-5.8-fold), fibroblast growth factor receptor 2 (-6.4-fold) and transforming growth factor ß receptor III (-8.2-fold) were also downregulated in SCC25 cells. DNA synthesis and repair gene products were differentially regulated in response to ionizing radiation in SCC25 cells (thymidylate synthetase, 6.4-fold; RAD51-like 1, -5.9-fold; RecQ protein-like 5, -6.1-fold; checkpoint suppressor 1, -6.2-fold). Phospholipase C ε1 and phospholipase D1 were downregulated by -5.0 and -5.3-fold, respectively. These results indicate that cell cycle regulatory genes in SCC25 cells were not as affected by ionizing radiation as NHEK cells.
To determine whether different DNA damaging agents regulated different sets of response genes, we exposed NHEK and SCC25 cells to cisplatin. The expression of 886 genes Table II . Gene expression changes between NHEK control and irradiated cells (840 differentially-expressed genes). Table III . Gene expression changes between SCC25 control and irradiated cells (468 differentially-expressed genes). ----------------------------------------------------------------------------------------------------- in NHEK cells was altered by cisplatin, compared to 351 differentially-expressed genes in the SCC25 line (Tables IV  and V) . Expression of terminal differentiation genes was again upregulated in NHEK cells (filaggrin, 14.6-fold; transglutaminase 5, 8.2-fold; suprabasin, 5.4-fold). Specific growth factor receptors were also downregulated (fibroblast growth factor receptor 3, -6.3-fold; fibroblast growth factor receptor 2, -6.6-fold). Cell cycle regulatory proteins were again downregulated by cisplatin in NHEK cells (cyclin A2, -6.3-fold; cyclin B2, -6.4-fold; cyclin B1, -7.8-fold), as were DNA Table IV . Gene expression changes between NHEK control and cisplatin-treated cells (886 differentially-expressed genes). 
-----------------------------------------------------------------------------------------------------
repair and replication genes (aurora kinase B, -5.3-fold; excision repair cross complementing 2, -5.5-fold; X-ray repair complementing 4, -6.3-fold; topoisomerase IIα, -7.4-fold). These results indicate that a common response to DNA damage exists in NHEK cells.
Similar genes were regulated in SCC25 cells exposed to cisplatin as in those treated with ionizing radiation. This set of genes was markedly different than those observed in NHEK cells. However, certain genes (e.g., polo-like kinase 1) were found downregulated by cisplatin in NHEK and SCC25 cells. Activating transcription factor 3, catenin ß1, suppressor of cytokine signaling 3, Rho family GTPase 1 and cyclin K were upregulated in response to both radiation and cisplatin. Fewer genes were downregulated in SCC25 cells treated with cisplatin than in those treated with ionizing radiation. These results indicate that a common response to DNA damage may exist in SCC25 cells.
We also treated NHEK and SCC25 cells with 5-FU, an inhibitor of DNA synthesis. The expression of 733 genes in NHEK cells was altered by 5-FU, compared to 565 differentially-expressed genes in the SCC25 line. Once again, a similar set of genes was differentially regulated in NHEK cells (Table VI) . Terminal differentiation gene products were upregulated (late cornified envelope 3D, 37.2-fold; small proline rich protein 2G, 14.4-fold; filaggrin, 13.0-fold; suprabasin, 6.1-fold). Cell cycle regulatory gene products were downregulated (cell division cycle 2, -5.0-fold; aurora kinase B, -6.5-fold; cyclin B2, -6.5-fold; topoisomerase IIα, -8.7-fold; Table V 
. Gene expression changes between SCC25 control and cisplatin-treated cells (351 differentially-expressed genes). -----------------------------------------------------------------------------------------------------Accession Gene symbol Gene name Fold change -----------------------------------------------------------------------------------------------------
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polo-like kinase 1, -25.0-fold, cyclin B1, -28.8-fold). In contrast, SCC25 cells exposed to 5-FU upregulated thymidylate synthetase 13.0-fold, checkpoint suppressor 1 (9.1-fold), catenin ß1 (9.0-fold), RAD52 homolog (5.8-fold) and epidermal growth factor receptor (5.6-fold) genes (Table VII) . RecQ protein-like 5 (-6.6-fold) and cyclin B1 (-7.6-fold) were downregulated by 5-FU in SCC25 cells. These results once again indicate a common set of differentially-expressed genes in response to DNA damage specific to NHEK or SCC25 cells.
To compare traditional DNA damaging agents to more targeted drugs, we treated NHEK and SCC25 cells with the telomerase inhibitor BIBR1532. Both early passage NHEK and SCC25 cells express telomerase, which maintains the ends Table VI . Gene expression changes between NHEK control and fluorouracil-treated cells (733 differentially-expressed genes). serine/threonine kinase 6 -9.0 AK026546 CXCL5 chemokine (C-X-C motif) ligand 5 -13.9 NM_005030 PLK1 polo-like kinase 1 Table VII . Gene expression changes between SCC25 control and fluorouracil-treated cells (565 differentially-expressed genes). --------------------------------------------------------------------------------------------------- -Table VIII . Gene expression changes between NHEK control and BIBR1532-treated cells (499 differentially-expressed genes). ----------------------------------------------------------------------------------------------------- of chromosomes. The expression of 499 genes in NHEK cells was altered by BIBR1532, compared to 140 differentiallyexpressed genes in the SCC25 line (Tables VIII and IX) . Treatment with BIBR1532 regulated different sets of genes in both NHEK and SCC25 cells. In NHEK cells, upregulated genes included thymidine kinase 2 (9.8-fold), connective tissue growth factor (9.7-fold), RAD51 homolog C (8.3-fold), vav3 oncogene (6.8-fold), SMAD3 (6.0-fold), CBP (5.9-fold), frizzled homolog 1 (5.3-fold) and Wnt10a (5.1-fold). Downregulated genes included thyroid hormone receptor α (-5-4-fold), desmocollin 2 (-5.7-fold), transglutaminase 1 (-8.8-fold), epidermal growth factor receptor (-10.6-fold) and cornifelin (-21.2-fold). Terminal differentiation gene products that were upregulated by radiation, cisplatin and 5-FU were downregulated by BIBR1532. In SCC25 cells, upregulated genes included Rac3 (8.8-fold), cytochrome P450 family 1 (6.9-fold), casein kinase 1ε (5.4-fold), breast cancer antiestrogen resistance 3 (5.4-fold) and thymidylate synthetase (5.0-fold). Downregulated genes included δ-like 3 (-5.2-fold), serine/threonine kinase 11 (-5.3-fold), c-fos (-5.5-fold), DNA polymerase α (-5.9-fold), phospholipase C ß2 (-5.9-fold) and c-jun (-7.9-fold). Few classic cell cycle regulatory proteins were affected by BIBR1532 treatment in NHEK and SCC25 cells. These results indicate that the telomerase inhibitor BIBR1532 does not regulate the same gene sets as do DNA damaging agents.
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Discussion
The results of this study indicate that squamous carcinoma cells express higher levels of a number of genes involved in DNA replication and repair. These genes include RAD51C, Fanconi anemia complementation group B, RAD1 homolog, RAD52 homolog B, mutS homolog 5, X-ray repair comple- Table IX . Gene expression changes between SCC25 control and BIBR1532-treated cells (140 differentially-expressed genes). 
-----------------------------------------------------------------------------------------------------
menting defective repair 3 and the mutY homolog. Other upregulated DNA synthesis genes included mitochondrial topoisomerase (DNA) I, thymidylate synthetase and DNA directed polymerase ε4. Functional studies will be required to determine whether these genes impart, to cancer cells, increased resistance to DNA damage. Additionally, the number of responsive genes was consistently lower in SCC25 cells exposed to radiation, cisplatin, 5-FU and BIBR1532. These data suggest that SCC25 cells exhibit decreased DNA damage response compared to NHEK cells. In order to overcome clinical drug resistance, it will be important to determine which genes contribute to this phenotype.
The response of NHEK cells to DNA damaging agents demonstrates a number of common features. DNA damage induces a number of terminal differentiation genes, including late cornified envelope 3D, corneodesmosin, filaggrin, transglutaminase 5 and suprabasin. It has been shown that ionizing radiation induces filaggrin expression in mouse epidermis (17, 18) . A number of histone genes were upregulated by DNA damaging agents, which may act to repress transcription or function in DNA repair. Cisplatin crosslinks have been shown to locally override the predefined rotational setting of positioned nucleosomes (19) . Activating transcription factor 3 was upregulated by DNA damaging agents in NHEK and SCC25 cells; although this had been demonstrated previously, the function of this gene in this response is unknown (20) . Transforming growth factor ß genes were upregulated, which inhibits proliferation of stratified epithelia. This function is consistent with growth inhibition following DNA damage.
Specific classes of genes were downregulated following DNA damage. These groups of genes were inhibited regardless of the type of DNA damage. Both G1 and G2 phase cyclins were inhibited by DNA damaging agents. The G2 phase cyclindependent kinase cdc2 was also inhibited, consistent with activation of the G2 checkpoint. DNA replication and repair genes were also downregulated, including FANCA, ERCC2, XPD and topoisomerases. XPD overexpression resulted in cisplatin resistance in glioma cell lines (21) . Polo-like kinase 1, which was dramatically downregulated by DNA damage, has been shown to regulate exit from the G2 checkpoint (22) . Aurora kinase has been shown to regulate cisplatin resistance in ovarian cancer cells (23) . Expression of the forkhead transcription factor FOXO3A is induced by radiation exposure (24) , in agreement with our results.
Cells exposed to the telomerase inhibitor BIBR1532 experience loss of telomeric DNA over time, triggering a DNA damage response. Our data indicate that this DNA damage response is substantially different than that induced by direct acting agents. BIBR1532 does not induce differentiation markers in NHEK or SCC25 cells, as do the direct acting agents. The telomerase inhibitor does not inhibit cell cycle regulatory genes in the same manner as radiation, cisplatin and 5-FU. It should be noted that this study evaluated short term response to the telomerase inhibitor, which may be different than that of cells exposed to the drug for weeks or months. However, the SCC25 line was resistant to BIBR1532 even at 400 population doublings, suggesting that generalized drug resistance is a prominent feature of these cells. Future studies will determine how this common pathway of drug resistance can be modulated in cancer cells.
